Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib trial of ROSgard (RMC-035) for acute kidney injuries

Trial Profile

A Phase Ib trial of ROSgard (RMC-035) for acute kidney injuries

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2018 According to an A1M Pharma AB media release, this study is expected to begin in the first half of 2020, with a planned result reading approximately six months after study start.
    • 20 Sep 2018 New trial record
    • 15 Aug 2018 According to an A1M Pharma AB media release, after completion of phase 1 trial in healthy volunteers this trial is planned in patient group.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top